louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01492738: The Effect of Acupuncture on Anxiety and Working Memory
Official title: The Effect of Acupuncture on Anxiety and Working Memory
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Memory Impairment
Anxiety
Keywords: Acupuncture
anxiety
memory
Lead sponsor: National University of Health Sciences
Sponsor class: OTHER
First posted: 2011-12-15
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study endeavors to examine the relationship between acupuncture, anxiety, and performance on a test of working memory. In the study, all participants will complete the State-Trait Anxiety Inventory (STAI) survey to determine how anxious they are at the moment and how anxious they tend to be in general. Then ½ of subjects will receive acupuncture for 20 minutes and ½ will rest quietly for 20 minutes. After this period, all subjects will again complete the STAI survey. Then all subjects will complete the Automated Operations Span Task (AOSPAN) which is a computerized test of working memory. Statistical analysis will be performed to determine if acupuncture had any effect on State-level anxiety and on performance on the AOSPAN.


Eligibility criteria: Inclusion Criteria:

* Undergraduate University student
* Fluent in English
* Willing to receive acupuncture
* Aged 18-30
* In good health
* Not pregnant
* Not breastfeeding

Exclusion Criteria:

* Not an Undergraduate University student
* Not fluent in English
* Unwilling to receive acupuncture
* Under 18 years of age or older than 30 years of age
* Chronic disease
* Pregnant
* Breastfeeding

Primary outcomes:
measure: Change in anxiety level
timeFrame: Baseline and after1 hour
measure: Memory task
timeFrame: After 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Tiffani Kim Institute
state: Illinois
city: Wilmette
country: United States
facility: A Center for Oriental Medicine
state: Illinois
Study officials:
affiliation: National University of Health Sciences
name: Jason Bussell, MSOM, LAc
role: PRINCIPAL_INVESTIGATOR
affiliation: National University of Health Sciences
name: Hui Yan Cai, PhD, LAc
role: STUDY_DIRECTOR
References:
Clinical trial NCT06696638: Physiological Effects of Lung Impedance Tomography-Guided and Plat Pressure-Guided Phigh During APRV in Patients With ARDS
Official title: Physiological Effects of Lung Impedance Tomography-guided and Plat Pressure-guided Phigh During Airway Pressure Release Ventilation in Patients With Acute Respiratory Distress Syndrome
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: ARDS: Acute Respiratory Distress Syndrome
Keywords: ARDS
APRV
EIT
Phigh
Lead sponsor: Wuhan Union Hospital, China
Sponsor class: OTHER
Collaborators: name: Wuhan Union Hospital, China
First posted: 2024-11-20
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study aims to investigate the effects of EIT-guided and Pplat-guided Phigh settings on regional ventilation and perfusion in ARDS patients during APRV, while also examining the impact of different Phigh settings on gas exchange, respiratory mechanics, and hemodynamics.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with ARDS according to the 2023 global new definition of ARDS.
* Age ≥ 18 years.

Exclusion Criteria:

* Severe chronic obstructive pulmonary disease, severe asthma, pulmonary bullae, pneumothorax, subcutaneous emphysema, mediastinal emphysema, etc. · Contraindications for EIT, such as chest wound dressing, pacemaker implantation, defibrillator use, etc.
* Pulmonary interstitial disease.
* Uncorrected shock of various types.
* Intracranial hypertension.
* Pregnant and postpartum women.

Primary outcomes:
measure: The effects of Phigh guided by different methods on regional lung ventilation assessed by EIT
timeFrame: 1 Hour Post-Intervention
Secondary outcomes:
measure: Global inhomogeneity assessed by electrical impedance tomography
timeFrame: 1 Hour Post-Intervention
measure: Center of ventilation assessed by electrical impedance tomography
timeFrame: 1 Hour Post-Intervention
measure: ventilation/perfusion matching assessed by EIT
timeFrame: 1 Hour Post-Intervention
measure: Respiratory system compliance
timeFrame: 1 Hour Post-Intervention
measure: mean arterial pressure
timeFrame: 1 Hour Post-Intervention
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Wuhan Union hospital
state: Hubei
Study officials:
References:
Clinical trial NCT01501838: Pulmonary Hypertension Institutional Registry
Official title: Pulmonary Hypertension Institutional Registry at Hospital Italiano de Buenos Aires
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Death
Lead sponsor: Hospital Italiano de Buenos Aires
Sponsor class: OTHER
First posted: 2011-12-29
Enrollment: 0
Sex: ALL
Minimum age (years): 17
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults 17 yo or older, Any type of Pulmonary Hypertension except type II

Brief summary: The purpose of this study is to create a registry of patients with Pulmonary Hypertension who received medical care in the Hospital Italiano of Buenos Aires.

Detailed description: The Institutional Registry of Pulmonary Hypertension includes patients prospectively with incident pulmonary hypertension, and excludes type II Pulmonary Hypertension. It also includes prevalent cases from our HMO who had diagnosis prior the beginning of the registry.

Eligibility criteria: Inclusion Criteria:

* More 17
* Pulmonary Hypertension
* Systolic Pulmonary Pressure \>40 mmhg measured in a doppler echocardiogram,
* Systolic artery pressure \<25 in a pulmonary angiography

Exclusion Criteria:

* Non accept to participate
* Pulmonary Hypertension type II (Left cardiac disease)

Primary outcomes:
measure: Pulmonary hypertension prevalence and incidence
timeFrame: 1 year
Secondary outcomes:
measure: Mortality rate
timeFrame: 1 year
Other outcomes:
Locations:
city: Buenos Aires
country: Argentina
facility: Hospital Italiano de Buenos Aires
Study officials:
affiliation: Hospital Italiano de Buenos Aires
name: Diego H Giunta, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00963508: Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice
Official title: A Multi-Center Phase III Study to Evaluate Malathion Gel 0.5% Formulation, for the Control of Head Lice in Pediatric Subjects and Adult Subjects With Pediculosis Capitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Pediculosis
Keywords: Head Lice
Lead sponsor: Taro Pharmaceuticals USA
Sponsor class: INDUSTRY
First posted: 2009-08-21
Enrollment: 403
Sex: ALL
Minimum age (years): 2
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.

Detailed description: This is a Phase III, multi-center, investigator-blinded, two-arm, randomized, parallel group study, evaluating the safety and efficacy of a Malathion Gel, 0.5% formulation, manufactured by Taro. The objective is to show superiority of the novel product to an active control, Nix® Crème Rinse, manufactured by Insight Pharmaceuticals.

Eligibility criteria: Inclusion Criteria:

* Confirmed active head lice infestation

Exclusion Criteria:

* Allergy to pediculicides or hair care products
* Scalp conditions other than head lice
* Previous head lice treatment within the past 4 weeks
* Current antibiotic treatment

Primary outcomes:
measure: Proportion of Index Subjects Free of Any Lice 14 Days After Their Last Treatment in the Modified ITT (LOCF)
timeFrame: 3 weeks
Secondary outcomes:
measure: Proportion of Subjects Who Were Considered a Treatment Success 14 Days After Their First Treatment in the Modified ITT (LOCF).
timeFrame: 3 weeks
Other outcomes:
Locations:
city: Hot Springs
country: United States
facility: Investigator Site
state: Arkansas
city: Sacramento
country: United States
facility: Investigator Site
state: California
city: Kissimmee
country: United States
facility: Investigator Site
state: Florida
city: Miami
country: United States
facility: Investigator Site
state: Florida
city: Ormond Beach
country: United States
facility: Investigator Site
state: Florida
city: Picayune
country: United States
facility: Investigator Site
state: Mississippi
city: San Antonio
country: United States
facility: Investigator Site
state: Texas
Study officials:
References:
citation: Meinking TL, Vicaria M, Eyerdam DH, Villar ME, Reyna S, Suarez G. A randomized, investigator-blinded, time-ranging study of the comparative efficacy of 0.5% malathion gel versus Ovide Lotion (0.5% malathion) or Nix Creme Rinse (1% permethrin) used as labeled, for the treatment of head lice. Pediatr Dermatol. 2007 Jul-Aug;24(4):405-11. doi: 10.1111/j.1525-1470.2007.00460.x.
Clinical trial NCT04820608: Transepithelial Customized Cross-linking
Official title: Epithelium-on Customized Cross-linking for Keratoconus
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Keratoconus
Keywords: keratoconus
cross-linking
transepithelial
oxygen-boosted
customized
CXL
Lead sponsor: Ophthalmica Eye Institute
Sponsor class: OTHER
First posted: 2021-03-29
Enrollment: 50
Sex: ALL
Minimum age (years): 12
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Customized remodeled vision (CuRV) is a new corneal cross-linking protocol for keratoconus, combining a transepithelial approach with customized energy application. Our aim is to follow-up our patients and establish the short-and long-term results of CuRV.

Detailed description: Customized remodeled vision is a protocol for oxygen-boosted, tranespithelial cross-linking, customized to apply higher energy at the apex of the cone, relatively lower to the cone area and none to healthy cornea. Thus CuRV promises to halt keratoconus progression, simultaneously offering potential for relatively good visual rehabilitation.Our primary outcomes involve spectacle-corrected distance visual acuity and changes in corneal topography/tomography and OCT parameters. These parameters include Kmax, thinnest corneal pachymetry, maximal anterior and posterior elevation, the Fourier analysis-derived irregularity index, and demarcation line depth.

Eligibility criteria: Inclusion Criteria:

* Topographic evidence of keratoconus:
* maximum corneal curvature (Kmax) ≥47.00 D,
* localized steepening on topographic maps,
* localized elevation in the anterior and posterior corneal surfaces.

Exclusion Criteria:

* Hypersensitivity to riboflavin
* Thinnest corneal pachymetry \< 380 μm
* History of corneal surgery, including previous cross-linking
* Corneal scarring
* Aphakia
* Pseudophakia
* Any visually significant ocular condition

Primary outcomes:
measure: Spectacle-corrected distance visual acuity
timeFrame: 1-3-6 months, 1 year, 2 years
measure: Kmax
timeFrame: 1-3-6 months, 1 year, 2 years
Secondary outcomes:
measure: Demarcation line depth
timeFrame: 1 month
measure: Thinnest corneal pachymetry
timeFrame: 1-3-6 months, 1 year, 2 years
measure: Maximal anterior & posterior elevation
timeFrame: 1-3-6 months, 1 year, 2 years
measure: Fourier analysis-calculated maximum decentration
timeFrame: 1-3-6 months, 1 year, 2 years
measure: Regularization index
timeFrame: 1-3-6 months, 1 year, 2 years
Other outcomes:
Locations:
city: Thessaloníki
country: Greece
facility: Ophthalmica Eye Institute
state: Kalamaria
Study officials:
affiliation: Ophthalmica Eye Institute
name: Miltos Balidis, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Seiler TG, Fischinger I, Koller T, Zapp D, Frueh BE, Seiler T. Customized Corneal Cross-linking: One-Year Results. Am J Ophthalmol. 2016 Jun;166:14-21. doi: 10.1016/j.ajo.2016.02.029. Epub 2016 Mar 2.
Clinical trial NCT00564408: Carbachols Headache-inducing Effect and Changes in Cerebral Blood Flow in Migraine Patients
Official title: Experimental Study That Investigates the Effect of an Acetylcholine Analogue in Terms of Headache and Changes in Intra- and Extra-cerebral Vessels During and After Infusion of Carbachol
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Headache
Lead sponsor: Danish Headache Center
Sponsor class: OTHER
First posted: 2007-11-28
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to test if carbachol infusion induces headache in migraine subjects as well as intra- and extra-cerebral vasodilatation.

Detailed description: To test if infusion of Carbachol induces headache in 12 migraine subjects as well as intra- and extra-cerebral vasodilatation in a double-blinded study

Eligibility criteria: Inclusion Criteria:

* Migraine without aura
* Weight 50-100 kg

Exclusion Criteria:

* Other significant diseases
* Migraine 5 days prior to experiment

Primary outcomes:
measure: Headache response after Carbachol infusion
timeFrame: 1 day after infusion
Secondary outcomes:
Other outcomes:
Locations:
city: Glostrup
country: Denmark
facility: Danish Headache Center
Study officials:
affiliation: Danish Headache Center
name: Henrik Schytz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03901508: A Single Session of tDCS (Transcranial Direct Current Stimulation) Improves Endurance for 30 Minutes
Official title: A Single Session of a-tDCS Improves Lower Limb Endurance for 30 Minutes in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Athlete
Healthy
Keywords: tDCS
Athlete
Isokinetic
Strength
Endurance
Lead sponsor: University of Liege
Sponsor class: OTHER
First posted: 2019-04-03
Enrollment: 20
Sex: MALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized, triple-blind, sham-controlled, crossover
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Healthy recreational athletes will undergo a session of anodal tDCS (transcranial direct current stimulation) or sham tDCS.

The primary outcome is an isokinetic evaluation of their hamstrings' and quadriceps' strength before and after each session

Detailed description: Healthy recreational athletes will be recruited through social media and advertisements.

Each subject came to the Liege University Hospitals' isokinetic lab. Each session began with strapping the subjet into the isokinetic machine, making sure that all the settings were adapted to the subject. Then, each subject underwent a concentric and eccentric isokinetic test of their lower limbs (dominant or non-dominant side depending on their group). Subjects then received either anodal tDCS, of sham tDCS. Neither the evaluator or the subject knew which they were receiving. Immediately following tDCS, there was a another isokinetic test, and 30 minutes after the second test, a subjects underwent a third test.

Eligibility criteria: Inclusion Criteria:

* Between 3 and 5 hours of sport a week
* Right handed and footed

Exclusion Criteria:

* One on the TSST (in high and relatively high risk sections)
* Previous neurological or orthopedic pathologies affecting limbs

Primary outcomes:
measure: Isokinetic Peak Strength
timeFrame: Changes between prior to tDCS, immediately following tDCS and 30 minutes after tDCS
measure: Isokinetic Work
timeFrame: Changes between prior to tDCS, immediately following tDCS and 30 minutes after tDCS
Secondary outcomes:
Other outcomes:
Locations:
city: Liege
country: Belgium
facility: Liege Univeristy Hospital
Study officials:
affiliation: Liege University Hospital
name: Stephen Bornheim, Msc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03007108: Age-dependency of Thrombin Generation Using a New Standardized Assay
Official title: Determination of Normal Range Values of Thrombin Generation Parameters in Pediatrics Population Using a New Standardized Thrombin Generation Assay
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Infants
Lead sponsor: CHU de Reims
Sponsor class: OTHER
First posted: 2017-01-02
Enrollment: 270
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The aim of this study is to establish normal values of thrombin generation assay parameters in pediatrics, according to different age groups. The standardized thrombin generation assay "Genesia™" will be used. Different age groups of healthy children will be recruited : neonates, 1-3 months, 3-6 months, 6-12 months, 1-2 years, 2-6 years, 6-12 years, and 12-15 years old. Adults values will be obtained (healthy adults \> 18 years old).

Detailed description: Materials and Methods Collection of blood samples Blood samples of 240 healthy children will be obtained from the blood that will be collected for the routine coagulation screening (in neonates and in children \< 18 months) or at the time of surgery in children aged \> 18 months. Healthy neonates will be recruited by the neonatologists. Children aged from 1 month to 15 years will be included by anesthesiologists before minor elective surgery such as tonsillectomy, adenoidectomy, phimosis or oral surgery. Additionally, blood from adults referred for thrombophilia testing will be studied. This study was approved by French authorities (ANSM and CPP). Inform consent will be obtained from all participants. Blood will be collected into plastic tubes containing sodium citrate (0.106 M, tubes from "Starstedt"). Platelet poor plasma will be obtained by two centrifugations for 10 minutes at 2500 g at room temperature and stored at - 70°C until further examination.

Statistical analysis Statistical analysis will be performed as 1) a descriptive analysis (frequency and percentage for qualitative data, mean, SD and centiles for quantitative data), and 2) a comparison analysis (student, Mann-Withney, Kruskall- Wallis).

Eligibility criteria: Inclusion Criteria:

* Informed consent from parents of children
* Informed consent from patients in the case of adults refered for thrombophilia testing
* Affiliation to the French Health Social System

Exclusion Criteria:

* weight \< 3250 g
* Patients under law protection

Primary outcomes:
measure: Thrombin generation
timeFrame: Day 0
Secondary outcomes:
Other outcomes:
Locations:
city: Reims
country: France
facility: Chu Reims
Study officials:
References:
Clinical trial NCT01029808: Bleeding Symptoms of Carriers of Hemophilia A and B
Official title: Bleeding Symptoms of Carriers of Hemophilia A and B
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hemophilia
Keywords: carriers of hemophilia
Lead sponsor: Sahlgrenska University Hospital
Sponsor class: OTHER
First posted: 2009-12-10
Enrollment: 126
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Carriers of severe and moderate hemophilia A and B

Brief summary: To collect and analyze data on female carriers of severe and moderate hemophilia A and B.


Eligibility criteria: Inclusion Criteria:

* Female carriers of hemophilia A and B.

Exclusion Criteria:

* Pregnancy.

Primary outcomes:
measure: Bleeding tendency in carriers of severe and moderate haemophilia compared to a control group.
timeFrame: Five years
Secondary outcomes:
Other outcomes:
Locations:
city: Göteborg
country: Sweden
facility: Sahlgrenska university hospital
Study officials:
name: Fariba Baghaei, MD PhD
role: STUDY_CHAIR
References:
citation: Olsson A, Hellgren M, Berntorp E, Ljung R, Baghaei F. Clotting factor level is not a good predictor of bleeding in carriers of haemophilia A and B. Blood Coagul Fibrinolysis. 2014 Jul;25(5):471-5. doi: 10.1097/MBC.0000000000000083.
citation: Olsson A, Hellgren M, Berntorp E, Baghaei F. Association between bleeding tendency and health-related quality of life in carriers of moderate and severe haemophilia. Haemophilia. 2015 Nov;21(6):742-6. doi: 10.1111/hae.12796. Epub 2015 Sep 8.
Clinical trial NCT06094608: IBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms
Official title: IBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Inflammatory Bowel Diseases
Ulcerative Colitis
Crohn Disease
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2023-10-23
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This research study is testing whether changes in sleep timing and morning light treatment may have an impact on symptoms related to inflammatory bowel disease.

Detailed description: This study will test a consumer health light therapy device (Re-Timer) for people with inflammatory bowel disease to better understand how it affects IBD-related quality of life.

Eligibility criteria: Inclusion Criteria:

* Biopsy-proven IBD
* Active IBD symptoms
* Impaired IBD quality of life
* Age \>/=18 years old
* Fluency in English
* Physically able to travel for study visits

Exclusion Criteria:

* Ileostomy, colostomy, ileoanal pouch, or ileorectal anastomoses, are planned for imminent surgery and/or have short bowel syndrome
* Other significant chronic disease
* Retinal pathology, history of eye surgery, taking photosensitizing medications
* Recent history of light treatment
* Lifetime psychotic or bipolar disorder
* Acute suicidal ideation
* Substance use disorder in the past 3 months, cannabis use \>1/week
* High risk for or diagnosed with obstructive sleep apnea, and/or narcolepsy
* Severe hearing problem, intellectual disability or serious cognitive impairment
* Pregnant, trying to get pregnant, or breastfeeding
* Night work or travel outside the eastern time zone in the past month

Primary outcomes:
measure: Change in Short IBD Questionnaire (SIBDQ) score
timeFrame: Baseline, post-treatment approximately 36 days
Secondary outcomes:
measure: Change in Patient Health Questionnaire 9 (PHQ-9) score
timeFrame: Baseline, post-treatment approximately 36 days
measure: Change in Patient-Reported Outcomes Measurement Information System Sleep Disturbance (PROMIS) Short-Form 8b
timeFrame: Baseline, post-treatment approximately 36 days
measure: For patients with Crohn's Disease (CD) - Change in Harvey Bradshaw Index (HBI)
timeFrame: Baseline, post-treatment approximately 36 days
measure: For patients with Ulcerative Colitis (UC) - Change in Simple Clinical Colitis Activity Index (SCCAI)
timeFrame: Baseline, post-treatment approximately 36 days
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Helen Burgess, Ph.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Michigan
name: Cathy Goldstein, M.D., M.S.
role: PRINCIPAL_INVESTIGATOR
References: